Fecal Calprotectin Testing

Description

Calprotectin is a calcium- and zinc-binding protein that is a potential marker of intestinal inflammation. Fecal calprotectin testing is proposed as a noninvasive means to diagnose inflammatory bowel disease (IBD). Other potential uses are to evaluate treatment response for patients with IBD and as a marker of relapse.

OBJECTIVE

The objective of this evidence review is to determine whether fecal calprotectin testing improves the net health outcome in individuals with or suspected of having inflammatory bowel disease.

POLICY STATEMENT

Fecal calprotectin testing may be considered medically necessary for the evaluation of patients when the differential diagnosis is inflammatory bowel disease or noninflammatory bowel disease (including irritable bowel syndrome) for whom endoscopy with biopsy is being considered.

Fecal calprotectin testing is considered investigational in the management of inflammatory bowel disease, including the management of active inflammatory bowel disease and surveillance for relapse of disease in remission.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
POLICY GUIDELINES

A fecal calprotectin level of less than 50 g/g is suggestive of a low likelihood of inflammatory bowel disease.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

In March 2006, the PhiCal (Genova Diagnostics), an enzyme-linked immunosorbent assay test for measuring concentrations of fecal calprotectin in fecal stool, was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. This test is indicated as an aid in the diagnosis of IBD and to differentiate IBD from irritable bowel syndrome, when used with other diagnostic testing and clinical considerations.

The PhiCal, as modified by Quest Diagnostics, is classified as a laboratory-developed test. Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. The modified PhiCal is available under the auspices of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing.

In 2014, CalPrest (Eurospital SpA) and, in 2016, CalPrestNG (Eurospital SpA) were cleared for marketing by FDA through the 510(k) process. According to the FDA summary, CalPrest "is identical" to the PhiCal™ test in that they have the same manufacturer. Compared with CalPrest, the "differences in CalPrest NG include the name of the test on the labels, detection antibody, the use of a Horse-radish peroxidase/TMB conjugate/substrate system, the provided Stop solution, the concentration of calibrators and controls in the kit and the dynamic range of the assay."

FDA product code: NXO-

Rapid fecal calprotectin tests that can be used in the home or physician's office are commercially available in Europe and Canada (eg, Calprosmart, Calpro AS; Quantum Blue Calprotectin, Bhlmann Laboratories). Rapid tests have not been approved by FDA for use in the United States.

RATIONALE

Summary of Evidence

For individuals who have a suspicion of IBD when endoscopy with biopsy is being considered who receive fecal calprotectin testing to select patients who can forgo endoscopy, the evidence includes prospective and retrospective diagnostic accuracy studies and systematic reviews. Rrelevant outcomes are test validity, symptoms, change in disease status, quality of life, hospitalizations, and medication use. Twenty-eight studies in a systematic review evaluated the diagnostic accuracy of fecal calprotectin in patients suspected of having IBD for whom noninflammatory bowel disease, such as irritable bowel syndrome, remains a consideration. Studies varied in the fecal calprotectin protein level cutoff used to indicate the presence of disease but most used a cutoff of 50 μg/g, which is the recommended lower bound. Studies have indicated that, at this threshold, the test has a sensitivity of 93% to 99% for IBD and a negative predictive value of 73% to 100% for intestinal inflammation. Out of 100 cases of suspected IBD, approximately 49 invasive tests would be avoided with 1 case missed. Therefore, fecal calprotectin can be used to inform a decision of whether to proceed with endoscopy. Clinical input supported that the use of fecal calprotectin testing for individuals with suspected IBD provides a clinically meaningful improvement in net health outcome by providing clinically valid and clinically useful information to guide the clinical decision-making. Specifically, fecal calprotectin testing can inform the decision by using a positive fecal calprotectin result to refer for endoscopy with biopsy or to use a negative fecal calprotectin results to exclude inflammatory bowel disease and avoid endoscopy with biopsy with acceptably low tradeoffs in missed diagnoses of IBD in those who have false negative FCP results. Input further highlighted that the use of fecal calprotectin is particularly important in pediatric populations, where children may not be able to fully participate as medical historians and may have non-specific and/or atypical symptoms. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
For individuals who have active IBD who receive fecal calprotectin testing to monitor disease activity, the evidence includes prospective and retrospective diagnostic studies, systematic reviews, and a randomized controlled trial (RCT). Relevant outcomes are test validity, symptoms, change in disease status, quality of life, hospitalizations, and medication use. RCTs are needed to determine whether guiding treatment based on fecal calprotectin levels can improve disease management. A 2017 RCT included fecal calprotectin as one of several indicators of inflammation to test the effect of tight control of IBD on health outcomes. The independent contribution of fecal calprotectin could not be determined from this study design. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have IBD in remission who receive fecal calprotectin testing to predict relapse, the evidence includes prospective and retrospective diagnostic studies, systematic reviews, and an RCT. Relevant outcomes are test validity, symptoms, change in disease status, quality of life, hospitalizations, and medication use. One RCT found no significant difference in the rate of relapse in patients whose medication was modified based on fecal calprotectin or standard clinical indicators, however, this RCT had design and conduct limitations that affected the interpretation of its results. Further study in high-quality RCTs is needed to determine whether adding fecal calprotectin to standard clinical practice improves the management of IBD patients in remission. The evidence is insufficient to determine the effects of the technology on health outcomes.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

American College of Gastroenterology

The American College of Gastroenterology (2018) published guidelines on the management of Crohn disease in adults. The College gave a strong recommendation based on a moderate level of evidence that fecal calprotectin is a helpful test that should be considered to differentiate the presence of inflammatory bowel disease from irritable bowel syndrome. A summary statement without a recommendation indicated that fecal calprotectin measurements may have an adjunctive role in monitoring disease activity.

National Institute for Health and Care Excellence

The National Institute for Health and Care Excellence (2013; recommendation 1.1 was updated in 2017), published guidance on fecal calprotectin testing for inflammatory diseases of the bowel. The guidance made the following recommendations:

1.1 "Faecal calprotectin testing is recommended as an option to support clinicians with the differential diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) in adults with recent onset lower gastrointestinal symptoms for whom specialist assessment is being considered, if:

• cancer is not suspected, having considered the risk factors (for example, age)...

1.2 Faecal calprotectin testing is recommended as an option to support clinicians with the differential diagnosis of IBD or non-IBD (including IBS) in children with suspected IBD who have been referred for specialist assessment...."

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.


The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
**POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2012</td>
<td>New policy</td>
<td>Fecal calprotectin testing is considered not medically necessary in the diagnosis and management of intestinal conditions, including the diagnosis and management of inflammatory bowel disease.</td>
</tr>
<tr>
<td>June 2013</td>
<td>Replace policy</td>
<td>Policy updated with new literature. No changes to policy statement. References updated.</td>
</tr>
<tr>
<td>June 2014</td>
<td>Replace policy</td>
<td>Policy updated with literature review. No change in policy statement. References 2, 5, 16 and 19 added; others renumbered or removed.</td>
</tr>
<tr>
<td>September 2015</td>
<td>Replace policy</td>
<td>Policy updated with literature review; references 2, 8, 15-16, and 21 added. No change in policy statement.</td>
</tr>
<tr>
<td>March 2017</td>
<td>Administrative review</td>
<td>Policy reviewed with no policy statement changes.</td>
</tr>
<tr>
<td>June 2018</td>
<td>Replace policy</td>
<td>Policy updated with literature review through January 8, 2018; references 4, 9-10, 12, and 18-19 added; references 17-18 updated; some references removed. Policy statement unchanged except “not medically necessary” corrected to “investigational” due to FDA 510k status</td>
</tr>
<tr>
<td>September 2019</td>
<td>Replace policy</td>
<td>Policy updated with literature review through September 7, 2018; reference 15 added. Policy statement revised; fecal calprotectin testing is considered medically for the evaluation of patients when the differential diagnosis is inflammatory bowel disease or irritable bowel syndrome for whom endoscopy with biopsy is being considered.</td>
</tr>
</tbody>
</table>

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.